Stanford's blood-cancer therapy treats first commercial patient
Following FDA approval, Stanford Medicine treated its first commercial patient with the Orca-T blood-cancer therapy, which reduces graft-versus-host diseas
Following FDA approval, Stanford Medicine treated its first commercial patient with the Orca-T blood-cancer therapy, which reduces graft-versus-host diseas